甲磺酸艾瑞布林与同步放疗用于转移性乳腺癌的安全性：单中心经验
Safety of eribulin mesylate and concomitant radiotherapy for metastatic breast cancer: a single-center experience.
作者信息
Meattini Icro, Desideri Isacco, Di Cataldo Vanessa, Francolini Giulio, De Luca Cardillo Carla, Scotti Vieri, Loi Mauro, Detti Beatrice, Mangoni Monica, Agresti Benedetta, Baldazzi Valentina, Greto Daniela, Casella Donato, Bernini Marco, Sanchez Luis Jose, Orzalesi Lorenzo, Nori Jacopo, Fambrini Massimiliano, Bianchi Simonetta, Livi Lorenzo
机构信息
Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
Department of Clinical & Experimental Biomedical Sciences, University of Florence, Florence, Italy.
出版信息
Future Oncol. 2016 May;12(9):1117-24. doi: 10.2217/fon-2015-0059. Epub 2016 Mar 9.
AIM
This study evaluates, for the first time, the safety of eribulin in metastatic breast cancer patients concomitantly treated with palliative radiotherapy (RT). Patients & materials: A total of 17 patients were pretreated for metastatic breast cancer. Patients received eribulin mesylate and bone RT.
RESULTS
The most frequent grade 3 hematologic adverse events were neutropenia (56%) and anemia (20%). Mean pain score decreased from 2 (baseline) to 0.7 (end of observation). Analgesic score remained stable (1.8 vs 1.6). Bone pain scores dropped within a few weeks and remained below baseline values throughout the analysis. The overall response rate was 29%, and the clinical benefit rate was 59%.
CONCLUSION
Eribulin is characterized by a manageable safety profile also when combined with palliative RT.
目的
本研究首次评估了艾瑞布林在接受姑息性放疗（RT）的转移性乳腺癌患者中的安全性。患者与材料：共有17例转移性乳腺癌患者接受了预处理。患者接受了甲磺酸艾瑞布林和骨放疗。
结果
最常见的3级血液学不良事件是中性粒细胞减少（56%）和贫血（20%）。平均疼痛评分从2（基线）降至0.7（观察结束时）。镇痛评分保持稳定（1.8对1.6）。骨痛评分在几周内下降，并且在整个分析过程中一直低于基线值。总缓解率为29%，临床获益率为59%。
结论
即使与姑息性放疗联合使用，艾瑞布林的安全性也易于管理。
Zotero 插件